The American College of Lifestyle Medicine (ACLM) has published a new expert consensus statement outlining the important role of lifestyle interventions in the treatment and prevention of major ...
GlobalData on MSN
J&J’s Caplyta doubles remission rate in MDD patients
Johnson & Johnson’s (J&J) Caplyta (lumateperone) plus antidepressants nearly doubled the likelihood of remission after six ...
BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback